Cancer Immune Resistance
Review Articles
Cancer immune resistance: can theories converge?
Oncogenic pathways as the basis of primary immune ignorance
The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy
The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions
Dissecting neutrophil complexity in cancer
Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers
Mesenchymal stromal cell plasticity and the tumor microenvironment
The TAM family as a therapeutic target in combination with radiation therapy
Checkpoint cluster: biomarkers of response
TREX1 is a checkpoint for innate immune sensing of DNA damage that fosters cancer immune resistance
-
Cover Image
Cover Image
Mapping gene signatures according to their expression in different immune landscapes of breast (BRCA), lung (LUAD) and colon (COAD) carcinoma, and melanoma (SKCM); signatures selectively expressed in the immune-active (ICR4) landscape are shown in red, those selectively expressed in the immune-silent (ICR1) landscape are shown as blue and those that are ubiquitously expressed independent of immune landscape are white. The image is based on Figure 1 in this issue's opening article (Lu et al., pages 411–419) in which the authors look at how cancer cells go through a conserved evolutionary bottleneck facing a Two-Option Choice to evade recognition by the immune competent host: they can either adopt a clean oncogenic process devoid of immunogenic stimuli (immune-silent tumors) or display an entropic biology prone to immune recognition (immune-active tumors).
